1,722,834 research outputs found
Computational Experience with a SDP-Based Algorithm for Maximum Cut with Limited Unbalance
No full textIn the Maximum Cut with Limited Unbalance problem, we want to partition the vertices of a weighted graph into two sets of sizes differing at most by a given threshold B, so that the sum of the weights of the crossing edges is maximum. This problem has been introduced in [Galbiati and Maffioli, Theor Comput Sci 385 (2007), 78–87] where polynomial time randomized approximation algorithms are proposed and their performance guarantees are analyzed in the case of non-negative integer weights. In this article, we present extensive computational experience with these algorithms on a large number of different graphs. We then extend the analysis of these algorithms to integer weights not restricted in sign, and continue the computational testing. It turns out that the approximation ratios obtained are always substantially better than those guaranteed by the theoretical analysis
La memoria come strumento di lotta: dall’incontro con Annie Ernaux
Get PDFIn October 2022, a few weeks after the announcement of the Nobel Prize, Annie Ernaux premiered in Italy her first film, Les Années Super8, released with her son David Ernaux-Briot. The extract below corresponds to a part of the dialogue between the French author and Francesca Maffioli, which took place in Bologna at Salaborsa Library during the XV edition of Archivio Aperto, the festival of Home Movies – National Family Film Archive
Effetti sulla variabilità glicemica e sul compenso glico-metabolico di metformina, pioglitazone e sitagliptin in pazienti affetti da diabete mellito di tipo 2
Get PDFScopo: il trattamento del diabete mellito di tipo 2 richiede spesso l'uso di più agenti ipoglicemizzanti per raggiungere un adeguato controllo glicemico. Scopo di questo studio è stato valutare gli effetti di una triplice terapia con metformina, pioglitazone e sitagliptin sul controllo glicemico e la variabilità glicemica rispetto a metformina e metformina + pioglitazone. Per valutare la variabilità glicemica è stato utilizzato un sistema di monitoraggio glicemico in continuo della glicemia.
Materiali e Metodi: sono stati arruolati 66 diabetici di tipo 2 non ben controllati. I pazienti hanno assunto per tre mesi metformina 500 mg tre volte al giorno, a cui è stato, poi, aggiunto pioglitazone 15 mg due volte al giorno per altri tre mesi ed, infine, sitagliptin 100 mg, una volta al giorno, per ulteriori tre mesi. Ad ogni fase dello studio, se il paziente raggiungeva l'obiettivo di emoglobina glicata (HbA1c) desiderato (<6.5%), veniva fatto uscire dallo studio. Abbiamo valutato: l'HbA1c, la glicemia a digiuno (FPG), la glicemia post-prandiale (PPG), l'insulinemia a digiuno (FPI), l'indice HOMA (HOMA-IR), la proteina C-reattiva ad alta sensibilità (hs-CRP), il profilo lipidico, la lipoproteina (a) [Lp(a)], la metalloproteinasi-2 (MMP-2), la metalloproteinasi-9 (MMP-9), le molecole di adesione (sICAM-1, sVCAM-1), la sE-selectina, l'adiponectina (ADN).
Risultati: abbiamo registrato una significativa riduzione di HbA1c, FPG, e PPG con metformina + pioglitazone (p < 0.05 vs basale), ed un’ulteriore riduzione con metformina + pioglitazone + sitagliptin (p < 0.01 vs basale). Abbiamo osservato un miglioramento del profilo lipidico rispetto al basale con metformina + pioglitazone + sitagliptin (p < 0.05 vs basale). C'è stata una riduzione di Hs-CRP, sICAM-1, sVCAM-1, ed un aumento di ADN con metformina + pioglitazone (p < 0.05 vs basale) e con metformina + pioglitazone + sitagliptin (p < 0.01 vs basale). i livelli di eSelectina si sono ridotti solo con metformina + pioglitazone + sitagliptin (p < 0.05 vs basale). Per quanto riguarda la variabilità glicemica, la deviazione standard è risultata minore con metformina + pioglitazone (p < 0.05 vs basale) e con metformina + pioglitazone + sitagliptin (p < 0.01 vs basale). Il valore M, indice di variabilità glicemica, è risultato più basso con metformina + pioglitazone + sitagliptin.
Conclusioni: la combinazione di metformina + pioglitazone + sitagliptin è risultata efficace nel migliorare il controllo glicemico e nel ridurre la variabilità glicemica e potrebbe essere un'opzione per il trattamento del diabete mellito di tipo 2.Background and aim: the treatment of type 2 diabetes mellitus often requires the use of one or more hypoglycemic agents to reach the adequate glycemic control. The aim of the study is to evaluate the effects of a triple therapy with metformin, pioglitazone and sitagliptin on glycemic variability compared to metformin monotherapy, and compared to a combination of metformin and pioglitazone. To assess glycemic variability a continuous glucose monitoring system was used. Material and Methods: we enrolled 66 not well controlled, type 2 diabetic patients. Patients were instructed to take metformin 500 mg three times a day for the first three months, then pioglitazone 15 mg twice a day was added for further three months, and finally sitagliptin 100 mg once a day was added for the last three months. At the baseline, and every three months a continuous glucose monitoring system was performed. At any stage of the study, if the value of glycated hemoglobin reached the desired goal (<6.5%), participation in the study was interrupted. We assessed: glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), post-prandial glucose (PPG), fasting plasma insulin (FPI), HOMA-index (HOMA-IR), high sensitivity C-reactive protein (hs-CRP), lipid profile, lipoprotein (a) [Lp(a)], metalloproteinase-2 (MMP-2), metalloproteinase-9 (MMP-9), soluble adhesion molecules (sICAM-1, sVCAM-1), sE-selectin, adiponectin (ADN).
Results: we recorded a significant decrease of HbA1c, FPG, and PPG with metformin + pioglitazone (p < 0.05 vs baseline), and a further decrease with metformin + pioglitazone + sitagliptin (p < 0.001 vs baseline). There was an improvement of lipid profile compared to baseline with metformin + pioglitazone + sitagliptin (p < 0.05 vs baseline). We recorded a decrease of Hs-CRP, sICAM-1, sVCAM-1, and an increase of ADN with metformin + pioglitazone (p < 0.05 vs baseline), and with metformin + pioglitazone + sitagliptin (p < 0.01 vs baseline). A decrease of eSelectin was recorded only with metformin + pioglitazone + sitagliptin (p < 0.05 vs baseline). Regarding glycemic variability, standard deviation was lower with metformin + pioglitazone (p < 0.05 vs baseline), and metformin + pioglitazone + sitagliptin (p < 0.01 vs baseline). The M value, an index of glycemic variability, was lower with metformin + pioglitazone + sitagliptin (p < 0.05 vs baseline).
Conclusion: combination of metformin + pioglitazone + sitagliptin proved to be effective in improving glycemic control, and in decreasing glycemic variability, therefore it could be suitable for the treatment of type 2 diabetic patients
Combinatorial Optimization-Polyhedra and Efficiency or All You Wanted to Know about Polyhedral Combinatorics and Never Dared to Ask
No full text
The Role of University-Driven Networks in the Industrial Development of Emerging Countries: the Case of Valparaíso Region en Chile
No full textThird ALIO-EURO meeting on Applied Combinatorial Optimization-Discrete Applied Mathematics
No full textNumero speciale di Discrte Applied Mathematics contenente le versioni definitive dei lavori selezionati tra quelli presentati al Convegno ALIO-EURO su Applied Combinatorial Optimization tenutosi a Erice nel Novembre 1999
Coloured Ant System and Local Search to Design Local Telecommunication Networks
Get PDFThis work combines local search with a variant of the Ant System recently proposed for partitioning problems with cardinality constraints. The Coloured Ant System replaces the classical concept of trail with p trails of different "colours", representing the assignment of an element to one of the classes in the partition. We apply the method with promising results to the design of local telecommunication networks. The combination of the Coloured Ant System with local search yields much better results than the two approaches alone
- …
